An immune class of HCC characterized by significant immune infiltration, specifically T lymphocyte infiltration with overexpression of PD-1/PD-L1 and CTLA4, is best suited for immune checkpoint inhibitor therapy. This evidence concerns the gene CD274 and hepatocellular carcinoma.